These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7467224)

  • 1. [Humoral antitumor cytotoxins in the ascitic forms of malignant ovarian tumors].
    Kondrat'eva AF; Livshits MA
    Vopr Onkol; 1980; 26(12):80-4. PubMed ID: 7467224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Assessment of the activity of tumor necrosis factor in normal state and in ovarian tumors].
    Koval'chuk LV; Pavliuk AS; Aksenova NIa; Iakovleva NV; Nalbandian SV; Ul'ianova TIu
    Biull Eksp Biol Med; 1990 Jun; 109(6):571-3. PubMed ID: 2397296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CA 125 in the diagnosis and evaluation of the efficacy of the treatment of cancer of the ovaries].
    Sagan DL; Chebotareva ED; Evtushenko GV
    Med Radiol (Mosk); 1989 Jun; 34(6):39-42. PubMed ID: 2739519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cellular and humoral immunity in patients with benign tumors and tumor-like formations of ovaries].
    Selezneva ND; Kadagidze ZG; Andikian SI; Veskova TK; Zhogoleva IB
    Sov Med; 1982; (4):37-41. PubMed ID: 6980484
    [No Abstract]   [Full Text] [Related]  

  • 5. [Correlation of the level of humoral cytotoxins and delayed hypersensitivity skin reactions with survival of patients with melanoma of the skin].
    Korosteleva TA; Vagner RI; Veresova OV; Potapenkova LS
    Vopr Onkol; 1983; 29(4):38-40. PubMed ID: 6858049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic effects of leukocytes and plasma on primary cultures of ovarian carcinoma.
    Halbrecht I; Komlos L
    Obstet Gynecol; 1974 Feb; 43(2):268-75. PubMed ID: 4810236
    [No Abstract]   [Full Text] [Related]  

  • 7. [Humoral antitumor cytotoxins in patients with melanoma of the skin].
    Korosteleva TA; Veresova OV; Khachaturian LM
    Vopr Onkol; 1975; 21(5):61-3. PubMed ID: 1210146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Symtomatology of immunobiological reactions in the early stage of cancer].
    Müller J; Sturík J; Kepertová A
    Wien Z Inn Med; 1966 Feb; 47(2):61-5. PubMed ID: 6005155
    [No Abstract]   [Full Text] [Related]  

  • 9. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients.
    Gordon IO; Freedman RS
    Clin Cancer Res; 2006 Mar; 12(5):1515-24. PubMed ID: 16533776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
    Young RH
    Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
    Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
    Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
    Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
    Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Presence of tumor-specific immunoglobulins in patients with serous papillary adenoma of the ovary].
    Montemagno U; Cardone A; Di Stefáno M
    Boll Soc Ital Biol Sper; 1969 Nov; 45(21):1353-6. PubMed ID: 4196112
    [No Abstract]   [Full Text] [Related]  

  • 15. [The concentration of cytotoxins in rat serum during the development of ascitic tumors].
    Kondrat'eva AV
    Vopr Onkol; 1972; 18(12):50-4. PubMed ID: 4349079
    [No Abstract]   [Full Text] [Related]  

  • 16. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
    Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
    Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Typical thyroid-type carcinoma arising in struma ovarii: a report of 4 cases and review of the literature.
    Roth LM; Miller AW; Talerman A
    Int J Gynecol Pathol; 2008 Oct; 27(4):496-506. PubMed ID: 18753973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immunologic responsiveness to extracts of ovarian epithelial tumors.
    Melnick H; Barber HR
    Gynecol Oncol; 1975 Mar; 3(1):77-86. PubMed ID: 168133
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
    Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
    Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.